Keyphrases
Ovarian Cancer
60%
Ovarian Cancer Patients
34%
Advanced Ovarian Cancer
31%
Overall Survival
24%
Tumor
19%
Epithelial Ovarian Cancer
15%
Progression-free Survival
14%
Breast Cancer
13%
Bevacizumab
12%
Chemotherapy
11%
Hazard Ratio
11%
Vulvar Cancer
10%
Residual Tumor
10%
Platinum-based Chemotherapy
9%
Plasminogen Activator inhibitor-1 (PAI-1)
8%
Confidence Interval
8%
Germany
8%
Obstetrics
7%
Paclitaxel
7%
Poor Prognosis
7%
Phase II Study
7%
Recurrent Ovarian Cancer
7%
Metastasis
7%
Urokinase-type Plasminogen Activator
7%
Primary Tumor
6%
Vulvar Squamous Cell Carcinoma
6%
FIGO Stage
6%
Breast Cancer Patients
6%
Tumor Cells
6%
Malignant Ascites
6%
Ovarian Carcinoma
6%
Prognostic Factors
6%
Ascites
6%
Carboplatin
6%
Ovarian Cancer Screening
6%
Phase II Trial
6%
ENGOT
6%
First-line Chemotherapy
5%
Pegylated Liposomal Doxorubicin
5%
Catumaxomab
5%
Olaparib
5%
Ovar
5%
Quality of Life
5%
Medicine and Dentistry
Ovarian Cancer
100%
Neoplasm
46%
Krukenberg Tumor
23%
Overall Survival
20%
Progression Free Survival
14%
Metastatic Carcinoma
13%
Ovarian Tumor
13%
Diseases
12%
Bevacizumab
12%
Breast Cancer
12%
Surgery
11%
Gynecology
11%
Hazard Ratio
10%
Malignant Neoplasm
10%
Vulvar Cancer
10%
Cytoreductive Surgery
9%
Recurrent Disease
9%
Plasminogen Activator Inhibitor-1
8%
Biological Marker
8%
Obstetrics
8%
Quality of Life
7%
Cancer
7%
Recurrent Ovarian Cancer
7%
Urokinase
7%
Primary Tumor
7%
Paclitaxel
7%
First-Line Chemotherapy
6%
Cancer Cell
5%
Olaparib
5%
Prognostic Factor
5%
Lymph Node Metastasis
5%
Messenger RNA
5%
Retroperitoneal Lymph Node Dissection
5%
Ascites
5%
